Medartis Sustainability Profile
Medartis AG, headquartered in Switzerland (CH), is a leading player in the medical device industry, specialising in innovative solutions for the treatment of bone fractures and deformities. Founded in 1997, the company has established a strong presence in Europe, Asia, and the Americas, focusing on advanced surgical techniques and high-quality implants. Medartis is renowned for its unique product offerings, including the patented locking plate systems and comprehensive range of surgical instruments designed for orthopaedic and trauma surgery. These products are distinguished by their precision engineering and commitment to enhancing patient outcomes. With a solid market position, Medartis has achieved significant milestones, including numerous regulatory approvals and partnerships with healthcare professionals worldwide, solidifying its reputation as a trusted provider in the orthopaedic sector.
DitchCarbon Score
How does Medartis's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medartis's score of 59 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medartis's reported carbon emissions
In 2024, Medartis reported total carbon emissions of approximately 2,603,971 kg CO2e, comprising 877,100 kg CO2e from Scope 1, 752,450 kg CO2e from Scope 2, and 974,421 kg CO2e from Scope 3 emissions. The Scope 3 emissions include significant contributions from upstream transportation and distribution (368,760 kg CO2e) and waste generated in operations (382,260 kg CO2e). Medartis has set ambitious climate commitments, aiming for a reduction of approximately 60% in its CO2 emissions by 2033 compared to 2023 levels. This target is verified externally to ensure accountability. Additionally, the company has committed to achieving a 90% reduction in Scope 1 and 2 emissions by 2050. The company’s near-term targets, aligned with the Science Based Targets initiative (SBTi), include a 65% reduction in absolute Scope 1 and 2 emissions by 2033, alongside a commitment that 67% of its suppliers will have science-based targets by 2029. Furthermore, Medartis aims to reduce Scope 3 emissions by 61.1% per million CHF value added by 2033. These initiatives reflect Medartis's dedication to sustainability and its proactive approach to addressing climate change within the healthcare equipment and supplies sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 795,000 | 000,000 | 000,000 |
| Scope 2 | 831,000 | 000,000 | 000,000 |
| Scope 3 | 10,000 | 0,000,000 | 0,000,000 |
How Carbon Intensive is Medartis's Industry?
How Carbon Intensive is Medartis's Location?
Medartis's Scope 3 Categories Breakdown
Medartis's Scope 3 emissions, which decreased by 51% last year and increased significantly since 2022, demonstrating supply chain emissions tracking. A significant portion of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 49% of total emissions under the GHG Protocol, with "Waste Generated in Operations" being the largest emissions source at 25% of Scope 3 emissions.
Top Scope 3 Categories
Medartis's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Medartis has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
B. Braun Melsungen AG
Globus Medical, Inc.
In2Bones SAS
Karl Leibinger Medizintechnik GmbH & Co. KG
Frequently Asked Questions
Common questions about Medartis's sustainability data and climate commitments